2023
Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial
Grilo C, Lydecker J, Jastreboff A, Pittman B, McKee S. Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial. Obesity 2023, 31: 2762-2773. PMID: 37751990, PMCID: PMC10600891, DOI: 10.1002/oby.23898.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderObesity statusLogistic regressionWeight lossPlacebo-controlled trialWeight loss outcomesPrevalent psychiatric disordersEvidence-based treatmentsPost-treatment assessmentBinge-eating frequencyGreater percentage weight lossMedication outcomesRemission ratePharmacological optionsPlaceboBupropionPsychiatric disordersPercentage weight lossMixed modelsDisordersObesityPatientsSignificant reductionWeight reduction
2016
Perceived weight discrimination and chronic medical conditions in adults with overweight and obesity
Udo T, Purcell K, Grilo CM. Perceived weight discrimination and chronic medical conditions in adults with overweight and obesity. International Journal Of Clinical Practice 2016, 70: 1003-1011. PMID: 28032427, PMCID: PMC5215793, DOI: 10.1111/ijcp.12902.Peer-Reviewed Original ResearchConceptsChronic medical conditionsStressful life eventsMedical conditionsObese adultsPhysical activityMajor chronic medical conditionsWeight discriminationOverweight/obese adultsLife eventsAcute stressful life eventsSociodemographic variablesOverweight/obesityPerceived Weight DiscriminationMultiple logistic regressionGender-stratified analysesDifferent medical conditionsSocioeconomic burdenMyocardial infarctionHigh cholesterolCardiac conditionsStomach ulcersLogistic regressionRelated conditionsObesityHealth effects